Thomas J. Nevill

4.1k total citations · 1 hit paper
99 papers, 2.5k citations indexed

About

Thomas J. Nevill is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Thomas J. Nevill has authored 99 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Hematology, 36 papers in Genetics and 24 papers in Oncology. Recurrent topics in Thomas J. Nevill's work include Acute Myeloid Leukemia Research (39 papers), Hematopoietic Stem Cell Transplantation (31 papers) and Acute Lymphoblastic Leukemia research (23 papers). Thomas J. Nevill is often cited by papers focused on Acute Myeloid Leukemia Research (39 papers), Hematopoietic Stem Cell Transplantation (31 papers) and Acute Lymphoblastic Leukemia research (23 papers). Thomas J. Nevill collaborates with scholars based in Canada, United States and Australia. Thomas J. Nevill's co-authors include John D. Shepherd, Donna E. Hogge, Cynthia L. Toze, Donna L. Forrest, Michael J. Barnett, Heather J. Sutherland, Stephen H. Nantel, Kenneth J. Kopecky, Richard A. Larson and Martin S. Tallman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Thomas J. Nevill

94 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

2013 460 citations Thomas J. Nevill, Joseph Brandwein et al. profile →

Peers

Countries citing papers authored by Thomas J. Nevill

Since Specialization

Citations

This map shows the geographic impact of Thomas J. Nevill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Nevill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Nevill more than expected).

Fields of papers citing papers by Thomas J. Nevill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas J. Nevill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Nevill. The network helps show where Thomas J. Nevill may publish in the future.

Co-authorship network of co-authors of Thomas J. Nevill

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas J. Nevill. A scholar is included among the top collaborators of Thomas J. Nevill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas J. Nevill. Thomas J. Nevill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry 2023 ·Leukemia & lymphoma ·Rena Buckstein, (unknown), Karen Yee, Michelle Geddes, Heather A. Leitch, (unknown), Versha Banerji, Brian Leber, (unknown), Ève St‐Hilaire, (unknown), Thomas J. Nevill, Mary‐Margaret Keating, John M. Storring, (unknown), (unknown), Derek Tang, (unknown), Chris Cameron, (unknown)	3
2	A young woman with persistent sore throat, Epstein–Barr virus, lymphadenopathy, and aberrant CD4 + CD7‐ T‐cells 2023 ·American Journal of Hematology ·(unknown), (unknown), Ryan J. Stubbins, (unknown), (unknown), Sara Belga, (unknown), Thomas J. Nevill, Luke Y. C. Chen	1
3	Granulomatous Myositis as a Manifestation of Chronic Graft-Versus-Host Disease: A Case Series and Review of the Literature 2022 ·Clinical Lymphoma Myeloma & Leukemia ·Claudie Roy, (unknown), (unknown), Peter W. Schütz, (unknown), Cynthia L. Toze, Thomas J. Nevill, (unknown)	3
4	Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population 2021 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), Yasser Abou Mourad, Donna L. Forrest, Alina S. Gerrie, Florian Kuchenbauer, Stephen H. Nantel, Sujaatha Narayanan, Thomas J. Nevill, Maryse Power, David Sanford, (unknown), Jennifer White, (unknown), Heather J. Sutherland, Kevin Song	2
5	Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort 2020 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), Donna E. Hogge, Donna L. Forrest, Sujaatha Narayanan, Maryse Power, Thomas J. Nevill, Florian Kuchenbauer, Monika Hudoba, Artur Szkotak, Joseph Brandwein, David Sanford	1
6	Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial 2020 ·The Lancet Haematology ·Irwin Walker, Tony Panzarella, Stephen Couban, Félix Couture, Gerald M. Devins, Mohamed Elemary, Geneviève Gallagher, Holly Kerr, John Kuruvilla, Stephanie J. Lee, John J. Moore, Thomas J. Nevill, Gizelle Popradi, Jean Roy, Kirk R. Schultz, David Szwajcer, Cynthia L. Toze, Ronan Foley	53
7	Pre-Transplant Vitamin D Deficiency is Associated with Inferior Overall Survival but not Associated with Relapse Free Survival or Cumulative Incidence of GVHD Post Adult Hematopoietic Cell Transplantation for Hematological Malignancies 2016 ·Biology of Blood and Marrow Transplantation ·Deepesh Lad, Yasser Abou Mourad, Michael J. Barnett, Donna L. Forrest, Alina S. Gerrie, Donna E. Hogge, Stephen H. Nantel, Sujaatha Narayanan, Thomas J. Nevill, Maryse Power, Kevin Song, Heather J. Sutherland, Cynthia L. Toze, Raewyn Broady	1
8	Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia 2016 ·Leukemia & lymphoma ·David Kliman, Michael J. Barnett, Raewyn Broady, Donna L. Forrest, Alina S. Gerrie, Donna E. Hogge, Stephen H. Nantel, Sujaatha Narayanan, Thomas J. Nevill, Maryse Power, David Sanford, Kevin Song, Heather J. Sutherland, Cynthia L. Toze, Yasser Abou Mourad	3
9	Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors 2015 ·Biology of Blood and Marrow Transplantation ·Anish Nair, Michael J. Barnett, Raewyn Broady, Donna E. Hogge, Kevin Song, Cynthia L. Toze, Stephen H. Nantel, Maryse Power, Heather J. Sutherland, Thomas J. Nevill, Yasser Abou Mourad, Sujaatha Narayanan, Alina S. Gerrie, Donna L. Forrest	17
10	Normal Karyotype CALLA-Positive Adult Pre-B ALL: Dismal Outcome With Chemotherapy for Patients With Loss/Gain of ABL1 and/or BCR FISH Signals 2012 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), (unknown), Hélène Bruyèrè, (unknown), Michael J. Barnett, Donna L. Forrest, Thomas J. Nevill, Cynthia L. Toze, Stephen H. Nantel, John D. Shepherd	1
11	Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy 2011 ·Leukemia & lymphoma ·Adisak Tantiworawit, Maryse Power, Michael J. Barnett, Donna E. Hogge, Stephen H. Nantel, Thomas J. Nevill, John D. Shepherd, Kevin Song, Heather J. Sutherland, Cynthia L. Toze, (unknown), Sujaatha Narayanan, Raewyn Broady, Donna L. Forrest	13
12	Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results 2008 ·Bone Marrow Transplantation ·Khaled M. A. Ramadan, Joseph M. Connors, Abdulwahab J. Al-Tourah, (unknown), Randy D. Gascoyne, Michael J. Barnett, Thomas J. Nevill, John D. Shepherd, S.H. Nantel, H.J. Sutherland, Donna L. Forrest, Donna E. Hogge, Julye C. Lavoie, (unknown), Mukesh Chhanabhai, Nicholas Voss, Ryan R. Brinkman, (unknown), Cynthia L. Toze	14
13	Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML 2008 ·Bone Marrow Transplantation ·Thomas J. Nevill, Donna E. Hogge, Cynthia L. Toze, S.H. Nantel, Maryse Power, (unknown), Kevin Song, Julye C. Lavoie, Donna L. Forrest, Michael J. Barnett, John D. Shepherd, (unknown), (unknown), Heather J. Sutherland, Clayton A. Smith	10
14	High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation 2005 ·Journal of Clinical Oncology ·Donna L. Forrest, Donna E. Hogge, Thomas J. Nevill, Stephen H. Nantel, Michael J. Barnett, John D. Shepherd, Heather J. Sutherland, Cynthia L. Toze, Clayton A. Smith, Julye C. Lavoie, Kevin Song, Nicholas Voss, Randy D. Gascoyne, Joseph M. Connors	39
15	Characteristics and outcome of patients developing endocarditis following hematopoietic stem cell transplantation 2004 ·Bone Marrow Transplantation ·John Kuruvilla, Donna L. Forrest, Julye C. Lavoie, S.H. Nantel, John D. Shepherd, (unknown), Heather J. Sutherland, Cynthia L. Toze, Donna E. Hogge, Thomas J. Nevill	14
16	Fulminant tumour lysis syndrome in acute myelogenous leukaemia with inv(16)(p13;q22) 2002 ·European Journal Of Haematology ·Matthew D. Seftel, Hélène Bruyèrè, Mhairi Copland, Donna E. Hogge, (unknown), S.H. Nantel, John D. Shepherd, Julye C. Lavoie, Alan Le, Heather J. Sutherland, Cynthia L. Toze, Thomas J. Nevill	8
17	Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease with Rabbit Antithymocyte Globulin 2000 ·Journal of Hematotherapy & Stem Cell Research ·(unknown), Thomas J. Nevill, M. J. Barnett, Cynthia L. Toze, Craig J. Currie, H.J. Sutherland, Eibhlin Conneally, John D. Shepherd, SH Nantel, Donna E. Hogge, Hans-Georg Klingemann	53
18	Apoptosis is the mode of keratinocyte death in cutaneous graft-versus-host disease 1996 ·Journal of the American Academy of Dermatology ·Richard G. Langley, Noreen M. Walsh, Thomas J. Nevill, Lynn N. Thomas, (unknown)	33
19	Busulfan, cyclophosphamide, and melphalan conditioning for autologous bone marrow transplantation in hematologic malignancy. 1991 ·Journal of Clinical Oncology ·G. L. Phillips, John D. Shepherd, M. J. Barnett, P. M. Lansdorp, Hans-Georg Klingemann, John J. Spinelli, Thomas J. Nevill, K. Arnold Chan, Donna Reece	39
20	Horner's syndrome and demyelinating peripheral neuropathy caused by high‐dose cytosine arabinoside 1989 ·American Journal of Hematology ·Thomas J. Nevill, Tim J Benstead, (unknown), (unknown)	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact